Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of September 2019. The report details a material amendment to a strategic collaboration agreement with Eli Lilly and Company regarding the development of Tau Morphomer small molecules for Alzheimer's disease and other neurodegenerative conditions.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data for the period. The primary financial disclosure relates to a specific contractual milestone payment:
- Total Milestone Payment: 60 million Swiss Francs (CHF) under the original License Agreement.
- Payment Structure: Divided into two installments of 30 million CHF each.
- First Installment Due: On or before October 7, 2019.
- Second Installment Due: On or before March 31, 2020, contingent on the agreement not being terminated earlier.
Material Changes
The material change reported is the execution of an amendment on September 19, 2019, to the License Agreement dated December 11, 2018. This amendment alters the timing of the first milestone payment, splitting the lump sum into two distinct tranches to be paid over a six-month period.
Outlook, Risks, and Contingencies
The receipt of the second installment of 30 million CHF is contingent upon Eli Lilly not terminating the License Agreement prior to March 31, 2020. The filing does not provide specific management commentary on future revenue guidance, operational risks, or other contingencies beyond the terms of this specific amendment.
Key Facts for Investor Verification
- Verify the receipt of the first 30 million CHF installment by the October 7, 2019 deadline.
- Monitor the status of the License Agreement to ensure no termination occurs before the March 31, 2020 payment date.
- Confirm the impact of this amendment on the company's cash flow projections for late 2019 and early 2020.
- Note that this filing does not contain updated financial statements; refer to the most recent Form 20-F for full financial position details.